Shanghai Junshi Biosciences Sees Strong Growth

Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.

Shanghai Junshi Biosciences reports a 17% revenue increase and a significant 50% rise in domestic sales of its core product TUOYI during the first half of 2024, despite a 42% cut in R&D expenses due to strategic cost control. The company also notes a 35% reduction in losses and maintains a robust cash position, while expanding its innovative R&D into various therapeutic areas and achieving international market penetration, including U.S. FDA approval and inclusion in health insurance lists.

For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.